TB
Thomas W. Beetham
Chief Operating Officer

Thomas W. Beetham insider trades: Viridian Therapeutics, Inc.\DE (VRDN) stock buys and sales

Chief Operating Officer, Viridian Therapeutics, Inc.\DE Last trade Sep 27, 2024 26 Form 4 filings
$0
Sold, last 12 months
0 sales
$0
Bought, last 12 months
0 buys
7
Open-market trades
since 2020
3
Companies
last trade 2024

Trades on the price chart

Daily close, with an arrow on each day they bought or sold

Companies

Where Thomas reports to the SEC

Open-market buys and sales

7 trades reported on SEC Form 4, newest first

DateStockTypeValue
Sep 27, 2024VRDN↑ Buy$117K
Sep 16, 2021MGTA↓ Sell$41K
Feb 3, 2021KNSA↓ Sell$55K
Jul 1, 2020KNSA↓ Sell$751K
Jun 10, 2020KNSA↓ Sell$345K
Apr 21, 2020KNSA↓ Sell$954K
Feb 14, 2020KNSA↓ Sell$1K

Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.

Other VRDN insiders

Open-market trades in the last 12 months

About Thomas W. Beetham's insider trades

Thomas W. Beetham is Chief Operating Officer at Viridian Therapeutics, Inc.\DE (VRDN). Since Feb 14, 2020, Thomas has reported 1 open-market purchase worth $117K and 6 sales worth $2.1M on SEC Form 4. There have been no open-market trades in the last 12 months.

Their filings also include grants and awards (17 filings), option exercises (2 filings), shares withheld for taxes (2 filings), conversions (2 filings). These aren't open-market trades and aren't counted above.

How to read insider trades

Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every VRDN insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.